pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jun 19·1 min read
save

Protego Biopharma appoints Jae Kim as chief medical officer

Jun 19, 2026·read at STAT ↗Neutral

Protego Biopharma announced the addition of Jae Kim to its executive team as chief medical officer.

Kim comes to Protego after serving as chief medical officer at both Septerna and Design Therapeutics, bringing experience from those roles.

The appointment was highlighted in STAT+ as part of its regular feature on industry personnel moves.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Up and down the ladder: The latest comings and goings”

read at STAT ↗
459 words · retrieved Jun 19
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Design Therapeutics, Inc.ELI LILLY COLILLYNOVORISING
drugs
Obesity
topics
ApprovalObesityOncology

related stories

  • Sep 286 immunology targets to sustain a mammoth I&I marketBioSpace
  • Sep 25Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s dataBioPharma Dive
  • Sep 23Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitzBioSpace
  • Sep 22STAT+: Novo may be getting a better deal than expected with Medicare’s Bridge programSTAT
  • Sep 15FDA clears first generic radioligand drug; Sionna turns to layoffsBioPharma Dive